SCHEMBL5752502

SCHEMBL5752502

Cn1c(CNC(=O)c2ccccc2Br)cc2ccccc21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.73
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
HPGD P15428 3/20 0.47
HTT P42858 2/20 0.47
TSHR P16473 1/20 0.45
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
BRCA1 P38398 1/20 0.44
CASP7 P55210 1/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1382066 0.81 NPC1 (0.77) POLBNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL18361820 0.79 POLB (0.65) POLBNPC1RAB9AKDM4E
SCHEMBL6949782 0.77 POLB (0.62) POLBNPC1RAB9AHTTSMN1; SMN2
SCHEMBL5753442 0.76 HPGD (0.56) POLBHPGD
SCHEMBL4843594 0.75 POLB (0.60) POLBNPC1RAB9A
SCHEMBL4794063 0.75 POLB (0.60) POLBNPC1RAB9AKDM4E
SCHEMBL31370016 0.71 POLB (0.55) POLBNPC1RAB9AALDH1A1HDAC3
SCHEMBL1092961 0.71 KDM1A (0.55) POLBNPC1RAB9AHPGDALDH1A1
Hydrochloric Acid SCHEMBL1376190 0.70 POLB (0.54) POLBNPC1RAB9AALDH1A1HDAC3
SCHEMBL28710986 0.70 KMT2A (0.62) POLBNPC1RAB9AHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1225894-B1 FAB I INHIBITORS AFFINIUM PHARM INC (CA) 2006-07-05 EP disclosed
US-6730684-B1 KEY REGULATORY POINT IN THE OVERALL SYNTHETIC PATHWAY OF BACTERIAL FATTY ACID BIOSYNTHESIS; FABI IS AN IDEAL TARGET FOR ANTIBACTERIAL INTERVENTION AFFINIUM PHARMACEUTICALS, INC. (CA) 2004-05-04 US disclosed